Background: This study investigated the accuracy of real-time continuous glucose monitoring (rtCGM) during high intensity interval training (HIIT) in patients with type 1 diabetes (T1D). Methods: Seventeen participants with T1D, using multiple daily injections (MDI) with basal insulin glargine 300 U/mL (Gla-300), completed four fasted HIIT sessions over 4 weeks while wearing a Dexcom rtCGM G4 Platinum system. Each exercise consisted of high intensity interval cycling and multimodal training over 25 min. Reference venous plasma glucose (PG) was measured at 60- and 10-min before exercise (Stage 1), every 10 min during exercise and then every 15 min until 180 min after the end of exercise (Stage 2: during exercise and 45-min early recovery; Stage 3: 45 min to 3 h after the end of exercise); and at 6-, 10-, and 13-h postexercise (Stage 4). Results: In the 64 HIIT sessions that resulted in hyperglycemia, PG increased 90.0 ± 32.4 mg/dL (mean ± standard deviation), peaking at 68.0 ± 18.4 min from the start of HIIT. Mean absolute relative difference was highest during exercise and early recovery (Stage 2) at 17.8%, versus Stage 1 (10.4%), Stage 3 (10.6%), and Stage 4 (11.5%) (P < 0.001). During Stage 2, rtCGM showed a significant negative bias of 35.3 mg/dL (P < 0.001) compared to reference glucose. Lag time to reach the half-maximal glucose rise was 35 min in rtCGM versus PG. The Surveillance Error Grid found that in Stage 2, only 65.5% of paired values were in the no-risk zone and the %15/15 was 50%, significantly lower than the other stages (P < 0.001). Conclusions: During HIIT and early recovery, there is an increase in lag time and a related decline in accuracy of Dexcom rtCGM G4, compared to pre-exercise and later recovery, in patients with T1D using MDI.
Background: This study investigated the accuracy of real-time continuous glucose monitoring (rtCGM) during high intensity interval training (HIIT) in patients with type 1 diabetes (T1D). Methods: Seventeen participants with T1D, using multiple daily injections (MDI) with basal insulin glargine 300 U/mL (Gla-300), completed four fasted HIIT sessions over 4 weeks while wearing a Dexcom rtCGM G4 Platinum system. Each exercise consisted of high intensity interval cycling and multimodal training over 25 min. Reference venous plasma glucose (PG) was measured at 60- and 10-min before exercise (Stage 1), every 10 min during exercise and then every 15 min until 180 min after the end of exercise (Stage 2: during exercise and 45-min early recovery; Stage 3: 45 min to 3 h after the end of exercise); and at 6-, 10-, and 13-h postexercise (Stage 4). Results: In the 64 HIIT sessions that resulted in hyperglycemia, PG increased 90.0 ± 32.4 mg/dL (mean ± standard deviation), peaking at 68.0 ± 18.4 min from the start of HIIT. Mean absolute relative difference was highest during exercise and early recovery (Stage 2) at 17.8%, versus Stage 1 (10.4%), Stage 3 (10.6%), and Stage 4 (11.5%) (P < 0.001). During Stage 2, rtCGM showed a significant negative bias of 35.3 mg/dL (P < 0.001) compared to reference glucose. Lag time to reach the half-maximal glucose rise was 35 min in rtCGM versus PG. The Surveillance Error Grid found that in Stage 2, only 65.5% of paired values were in the no-risk zone and the %15/15 was 50%, significantly lower than the other stages (P < 0.001). Conclusions: During HIIT and early recovery, there is an increase in lag time and a related decline in accuracy of Dexcom rtCGM G4, compared to pre-exercise and later recovery, in patients with T1D using MDI.
Entities:
Keywords:
Accuracy; Exercise; Glycemic control; High intensity interval training; Real-time continuous glucose monitoring (rtCGM); Type 1 diabetes
Authors: Michael Müller-Korbsch; Gersina Rega-Kaun; Peter Fasching; Maria Fangmeyer-Binder; Lisa Fruehwald; Michael Heer Journal: J Diabetes Sci Technol Date: 2021-08-15
Authors: Timothy A Rengers; Samantha C Orr; Charles R C Marks; Tamara Hew-Butler; Myung D Choi; Scotty J Butcher; Dorin Drignei; Elise C Brown Journal: J Sports Med (Hindawi Publ Corp) Date: 2021-04-30
Authors: Othmar Moser; Michael C Riddell; Max L Eckstein; Peter Adolfsson; Rémi Rabasa-Lhoret; Louisa van den Boom; Pieter Gillard; Kirsten Nørgaard; Nick S Oliver; Dessi P Zaharieva; Tadej Battelino; Carine de Beaufort; Richard M Bergenstal; Bruce Buckingham; Eda Cengiz; Asma Deeb; Tim Heise; Simon Heller; Aaron J Kowalski; Lalantha Leelarathna; Chantal Mathieu; Christoph Stettler; Martin Tauschmann; Hood Thabit; Emma G Wilmot; Harald Sourij; Carmel E Smart; Peter G Jacobs; Richard M Bracken; Julia K Mader Journal: Pediatr Diabetes Date: 2020-10-13 Impact factor: 4.866
Authors: Florian H Guillot; Peter G Jacobs; Leah M Wilson; Joseph El Youssef; Virginia B Gabo; Deborah L Branigan; Nichole S Tyler; Katrina Ramsey; Michael C Riddell; Jessica R Castle Journal: Biosensors (Basel) Date: 2020-09-29